COPENHAGEN, DENMARK – August 14, 2014 -

EBIT grew by 19%, and the EBIT margin increased by 3.5 percentage points to 28.1%. The higher EBIT

The full-year sales growth outlook is maintained. Full-year expectations for EBIT and net profit growth a

“It’s been a good first half for Novozymes”, says Novozymes CEO Peder Holk Nielsen. “Sales growth w

Novozymes’ executive leadership team will present the results at a conference call today at 12:00 pm C
ttp://www.novozymes.com/en/investor/events-presentations/Pages/conference-call.aspx

The entire earnings report can be downloaded at news.novozymes.com

About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of indus

www.novozymes.com
Europe
Frederik Bjørndal
Mobile: +44 (0) 7976 138 265
tfbh@novozymes.com
Denmark
René Tronborg
Office: +45 44462274
Mobile: +45 30772274
retr@novozymes.com

US
Paige Donnelly
Office: +1 919 494 3209
Mobile: +1 919 218 4501
pagd@novozymes.com
China
Lian Meng
Office: +86 106 298 7888+392
Mobile: +86 136 992 31164

mexl@novozymes.com

Brazil
Henrique Pellini
Office: +55 41 36411000
Mobile: +55 41 9288-0282
hqp@novozymes.com

India
Poonam Kapila
Mobile: +91 9910822339
poka@novozymes.com

INVESTOR CONTACTS

Europe
Thomas Steenbech Bomhoff
Office: +45 4446 1226
Mobile: +45 3077 1226
tsbm@novozymes.com
US
Martin Riise
Office: +1 919 494 3483
Mobile: +1 919 649 2565
mrsn@novozymes.com